Loading...
Loading...
Browse all stories on DeepNewz
VisitWill President-elect Trump endorse Medicare and Medicaid coverage for anti-obesity medications by March 2025?
Yes • 50%
No • 50%
Official statement or press release from President-elect Trump's administration
Biden Proposes $35 Billion Medicare, Medicaid Coverage for Wegovy and Ozempic
Nov 26, 2024, 01:01 PM
The Biden administration has proposed a new rule that would require Medicare and Medicaid to cover anti-obesity medications, including popular weight-loss drugs like Wegovy, Ozempic, Mounjaro, and Zepbound. Recognizing obesity as a disease that can be treated with medication, this move could potentially expand access to these treatments for an estimated 3.4 million Americans on Medicare and 4 million adults on Medicaid, reducing out-of-pocket expenses by up to 95%. Currently, Medicare is prohibited from covering drugs for weight loss. The Congressional Budget Office estimates that expanding Medicare coverage for these medications could cost taxpayers up to $35 billion over the next decade. The rule would need to be finalized by the incoming administration, suggesting that President-elect Trump would need to endorse it.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%
Stricter Regulations • 25%
Looser Regulations • 25%
No Change • 25%
New Initiatives • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Less than 1 million • 25%
More than 3 million • 25%
2 million to 3 million • 25%
1 million to 2 million • 25%
$30 billion to $35 billion • 25%
More than $40 billion • 25%
Less than $30 billion • 25%
$35 billion to $40 billion • 25%